CLINICAL TRIAL

Acetazolamide for Multiple Sclerosis

Waitlist Available · 18 - 65 · All Sexes · Houston, TX

This study is evaluating whether a drug that improves blood flow in the brain can improve the way in which MS lesions evolve.

See full description

About the trial for Multiple Sclerosis

Eligible Conditions
Multiple Sclerosis · Sclerosis

Treatment Groups

This trial involves 2 different treatments. Acetazolamide is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Acetazolamide
DRUG
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.
Placebo
DRUG

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acetazolamide
FDA approved

Eligibility

This trial is for patients born any sex between 18 and 65 years old. There are 4 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
The subject has not had any changes in therapy for any reason for the previous six months. show original
A score of 0-6.0 on the Expanded Disability Status Scale (EDSS) means that a person has minimal disability. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 1 year
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 1 year.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Acetazolamide will improve 1 primary outcome and 2 secondary outcomes in patients with Multiple Sclerosis. Measurement will happen over the course of 24 weeks and at 48 weeks.

Change in tissue integrity in areas with and without increased cerebral blood flow with intervention
24 WEEKS AND AT 48 WEEKS
The key secondary outcome is to determine change in tissue integrity from baseline to 24 weeks after acetazolamide (ACZ) therapy as determined using diffusion tensor imaging (DTI-MRI) measures of mean diffusivity and fractional anisotropy. These changes will be compared between regions with and without increased cerebral blood flow (>15% difference from baseline).
Change in global cerebral blood flow with intervention
24 WEEKS AND AT 48 WEEKS
The primary outcome is to determine the change in global cerebral blood flow (CBF) after 24 weeks relative to pre-treatment baseline. CBF is determined using two independent but well correlated magnetic resonance imaging (MRI) methods, pseudo-continuous arterial spin labeling and dynamic susceptibility contrast imaging.
Composite changes in disability measures after acetazolamide (ACZ) compared to baseline
1 YEAR
We will investigate composite changes in disability measures after acetazolamide (ACZ) compared to baseline. We define composite for an individual as at least one of: a) any decrease in Expanded Disability Status Score (EDSS), b) 20% reduction in time to complete 9-Hole Peg Test (9HPT) for either the dominant or non-dominant hand, c) 20% decrease in Timed 25-Foot Walk (T25FW) or d) a >= 4-point or 10% improvement in accuracy for Symbol Digit Modalities Test (SDMT).

Who is running the study

Principal Investigator
J. A. L.
Prof. John A. Lincoln, Assistant Professor
The University of Texas Health Science Center, Houston

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of multiple sclerosis?

The presentation might include many different signs, so the name'multiple sclerosis' could be applied to a variety of conditions. The signs and symptoms of MS might be similar to a variety of other diseases. Therefore, the general term "multiple sclerosis" is better understood as an umbrella term, which applies to a spectrum of conditions, rather than a specific disease. Also, not all conditions, in which signs and symptoms of MS are found, are the same as MS. Also, not all of the signs and conditions cause the same damage. Some damage is permanent, and tends not to be corrected. Such types of damage can be assessed with MRI and lesion detection.

Anonymous Patient Answer

What causes multiple sclerosis?

The exact cause of MS remains unknown, but it is likely multifactorial, including environmental, genetic, and unknown exposures. This is in contrast to the general population, where risk factors are thought to be mainly environmental.

Anonymous Patient Answer

What is multiple sclerosis?

The most common manifestation of MS is a progressive disability (87.6% in this series) with some of the patients having a relapsing-remitting pattern of disability course (33.3%). Most patients have a good functional remission. The MS Disease Severity Scale is a simple instrument that permits identification of disability evolution in MS.

Anonymous Patient Answer

What are common treatments for multiple sclerosis?

There is a lack of randomized trials on MS treatments and most treatment options are approved for chronic disease rather than for acute events (such as relapse) or for prevention of future relapse.

Anonymous Patient Answer

Can multiple sclerosis be cured?

The current knowledge or use of any non-validated, unproven, unconventional or unsupported treatment methods is discouraged against conventional medical treatment. This is the first survey to our knowledge in the international literature related to the issue of the non-validated use of the most recent treatment of multiple sclerosis patients. Results from a recent clinical trial of this study, however, are reassuring and suggest that there is no reason to discourage the use of conventional medical treatment in this group of patients.

Anonymous Patient Answer

How many people get multiple sclerosis a year in the United States?

The number of people who will be diagnosed with MS and the number of people who live with MS will be increasing. A more thorough understanding of MS will help improve the health and quality of life for those living with it. A greater understanding of the effects of MS will also help improve the care of those affected and their primary care providers.

Anonymous Patient Answer

Is acetazolamide safe for people?

The use of acetazolamide in people with normal baseline renal function or no previous adverse reactions to the drug is safe. Further investigation is required before the long-term effects of acetazolamide on renal and neurological functions can be assessed.

Anonymous Patient Answer

Is acetazolamide typically used in combination with any other treatments?

Patients were more likely to receive gabapentin when combined with an agent commonly used in their treatment of MS, implying that this practice has potential for the development of drug co-therapy. When combined, gabapentin was less likely to be used relative to monotherapy, which is in contrast to the practice of combining the two in combination with other agents that are commonly used in MS treatment. This contrasts to the use of other agents commonly used in MS treatment.

Anonymous Patient Answer

Does multiple sclerosis run in families?

Although families of relatives diagnosed with MS do show considerable variability in clinical phenotype, a large number of families of first-degree relatives (n=11) of new MS cases were found to share similar clinical phenotypes. Inherited MS appears to be a highly polygenic disease, in which most genetic determinants in the general population are not implicated.

Anonymous Patient Answer

What is the latest research for multiple sclerosis?

It looks like all of the previous efforts have been directed back to understanding why the disease starts in the first place, and then addressing that problem. Researchers are searching for treatments for MS that work, and are looking for people who respond to these treatments. That's all we have to do to go from the lab to the pharmacy.

Anonymous Patient Answer

What is the primary cause of multiple sclerosis?

The current prevailing view that MS is a demyelinating disease, with a probable initiating inflammatory process, that causes axonal damage followed by demyelination. This view is unlikely to be superseded by the advances in molecular neuroimmunology, since axonal damage is not always apparent in early-stage MS and can occur even in progressive MS. The development of MS is likely to be heterogeneous, which would allow a more rational approach to the understanding of the mechanisms of disease.

Anonymous Patient Answer

What are the common side effects of acetazolamide?

Although most of the side effects recorded in the literature are uncommon, some must be noted, particularly when using ATC as monotherapy. The possible side effects of ATC do not appear to occur frequently during the first month of treatment or following its cessation. However, the drug has to be carefully prescribed to avoid a number of unpleasant rare side effects like liver toxicity.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Multiple Sclerosis by sharing your contact details with the study coordinator.